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United StatesSummary well as bioactive molecules present in bile, including endogenousCholangiocytes, the cells lining bile ducts, are a heterogenous,
highly dynamic population of epithelial cells. While these cells
comprise a small fraction of the total cellular component of the
liver, they perform the essential role of bile modiﬁcation and
transport of biliary and blood constituents. From a pathophysio-
logical standpoint, cholangiocytes are the target of a diverse
group of biliary disorders, collectively referred to as the cholangi-
opathies. To date, the cause of most cholangiopathies remains
obscure. It is known, however, that cholangiocytes exist in an
environment rich in potential mediators of cellular injury,
express receptors that recognize potential injurious insults, and
participate in portal tract repair processes following hepatic
injury. As such, cholangiocytes may not be only a passive target,
but are likely directly and actively involved in the pathogenesis of
cholangiopathies. Here, we brieﬂy summarize the characteristics
of the reactive cholangiocyte and cholangiocyte responses to
potentially injurious endogenous and exogenous molecules, and
in addition, present emerging concepts in our understanding of
the etiopathogenesis of several cholangiopathies.
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
The intrahepatic bile ducts form a complex three-dimensional
network of conduits lined by a single layer of specialized epithe-
lial cells, the cholangiocytes. In addition to their role in bile mod-
iﬁcation and transport, cholangiocytes actively sense and respond
to the inﬂammatory environment associated with liver injury, asJournal of Hepatology 20
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derived, xenobiotic) molecules that modify cholangiocyte func-
tion and/or phenotype. These molecules, some potentially injuri-
ous, can induce cellular responses affecting repair and
remodeling of the biliary epithelium.
Key Points
• Cholangiocytes, the cells lining bile ducts, are a 
heterogenous, highly dynamic population of epithelial
cells that recognize and respond to insult and/or injury
(i.e., cholangiocyte reactivity)
• The molecular mechanisms regulating the 
cholangiocyte response to exogenous and 
endogenous insults is an active area of research that
continues to provide insight into the innate immune,
proinflammatory and reparative function of this 
epithelium
• Cholangiocytes are the target of a diverse group 
of biliary disorders of different etiopathogenesis, 
collectively referred to as cholangiopathies
• In a subset of cholangiopathies, the cholangiocyte
response to insult or injury and the resultant 
communication with resident and recruited cells, 
implicates the cholangiocyte as not only a target, 
but also likely a central and active candidate in the
initiation and propagation of disease
Cholangiocytes vary in size, shape, and function along the biliary
tree (i.e., are heterogeneous [1]), and animal models of biliary
injury show that the nature of the biliary insult can determine
which subpopulation of cholangiocytes is affected [2,3]. For
example, in response to acute injury, large cholangiocytes (i.e.,
those from larger ducts) proliferate and maintain normal biliary
homeostasis. In contrast, chronic injury promotes increased pro-
liferation of both large and small ducts and induces a reparative
process associated with ductular changes that may include not
only expansion of existing ducts, but also induction of liver pro-
genitor cells (i.e., ductular reaction) (reviewed in [4]). This heter-
ogeneity of response is consistent with and may account for the
differential distribution of cholangiopathies along the biliary tree.
Cholangiocytes are the target of a diverse group of biliary
disorders of different etiologies, collectively referred to as13 vol. 58 j 575–582
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Fig. 1. The role of cholangiocytes in cholangiopathies. Cholangiocytes recog-
nize potential insults (endogenous or exogenous) and respond through the
upregulation of proinﬂammatory mediators. These features are a component of
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cholangiopathies [5]. Here we present a pathogenic framework
for a subset of these disorders, namely idiopathic (i.e., primary
sclerosing cholangitis-PSC) and immune-mediated (i.e., primary
biliary cirrhosis-PBC) cholangiopathies, focusing primarily on
cholangiocyte responses to constituents of bile. At the center of
this conceptual framework is the concept of the ‘‘activated’’ or
‘‘reactive’’ cholangiocyte, characterized by an enhanced proin-
ﬂammatory response including the secretion of chemokines,
cytokines, growth factors, and morphogens that promote
increased cholangiocyte proliferation, and biliary remodeling.
These cholangiocytes participate in an intricate cross-talk
between a variety of resident and recruited cells, including hepa-
tocytes, progenitor cells, hepatic stellate cells, portal ﬁbroblasts,
and leukocytes (primarily macrophages, neutrophils, and lym-
phocytes). In yet to be fully characterized genetically susceptible
individuals, the exaggeration or derangement of cholangiocyte
responses to bioactive molecules and the ensuing reparative pro-
cesses are likely an essential component of disease evolution.
Identiﬁcation of the nature and origin of the insults and a more
comprehensive understanding of the molecular pathways regu-
lating reactivity and repair processes throughout the biliary tree,
are important and active areas of research that will likely identify
new therapeutic targets and approaches.the intricate crosstalk between a variety of resident and recruited cells, including
hepatocytes, progenitor cells, ﬁbroblasts and leukocytes, in an attempt to repair
the epithelium. In most cases, the proinﬂammatory response and injury/damage
to the biliary tree is resolved. However, in the genetically susceptible individual,
perpetuation of the repair response results in progressive liver injury and a
persistent inﬂammatory response, leading to chronic inﬂammation of the bile
ducts and ultimately, disease.The cholangiopathies
The cholangiopathies are a group of disorders that can be orga-
nized into several broad categories: immune-mediated, drug- or
toxin-induced, infectious, genetic, ischemic and idiopathic. How-
ever, these categories overlap and more than one pathogenic
mechanism may be operative in a given cholangiopathy. Despite
their heterogeneity, the cholangiopathies have in common a
number of cholangiocyte-associated processes that may contrib-
ute to their pathogenesis, including pro-inﬂammatory signaling,
innate-immune responses, proliferation, and differentiation.
These cholangiocyte processes, particularly in genetically suscep-
tible individuals, may become disrupted and set the stage for
other phenomena including aberrant biliary remodeling, chole-
stasis, and ﬁbrosis (Fig. 1).
Two of the cholangiopathies, PSC and PBC, are rare but impor-
tant causes of chronic liver disease. Both are characterized by
chronic inﬂammation of the bile ducts and follow a course that
generally progresses to biliary cirrhosis, portal hypertension,
and liver failure. From an epidemiological perspective, PBC, as
with most autoimmune diseases, primarily affects women
(>90% of cases) and is associated with a variety of extrahepatic
autoimmune conditions including sicca syndrome, connective
tissue disease (e.g., systemic sclerosis), and autoimmune thyroid
disorders, among others. In contrast, PSC, which is considered idi-
opathic, likely immune-mediated but not autoimmune, is more
common in males, has not been shown to respond to immuno-
suppression and is frequently associated with inﬂammatory
bowel disease (IBD). Indeed, IBD (most often ulcerative colitis)
is found in approximately 75% of PSC patients [6,7]. The relation-
ship between IBD and PSC remains obscure, yet forms the basis
for several hypotheses, including the ‘‘leaky gut’’ and ‘‘aberrant
gut lymphocyte homing’’ hypotheses. The ‘‘leaky gut’’ hypothesis
suggests that PSC is caused, in susceptible individuals, by expo-
sure of the biliary tree to microbes or metabolites of enteric mic-
robiota (e.g., endotoxins, metabolites), while the ‘‘aberrant gut
lymphocyte homing’’ hypothesis suggests that mucosal lympho-576 Journal of Hepatology 201cytes from the diseased gut are recruited to the hepatobiliary
tract in response to adhesion molecules and chemokines that
are normally restricted to the gut [8].
As with most cholangiopathies, particularly in the early
stages, PBC and PSC generally affect distinct regions of the biliary
tree. Bile duct destruction in PBC is limited to small interlobular
and septal bile ducts, while in PSC, the larger intra- and extrahe-
patic bile ducts are preferentially affected. Although both PSC and
PBC increase the risk of hepatocellular carcinoma, unlike PBC, PSC
is also a major risk factor for cholangiocarcinoma, occurring in
approximately 0.5% per year, and does not require a background
of cirrhosis [9,10]. Optimal cancer surveillance in PSC patients is
an area of ongoing investigation.
With respect to pharmacotherapy, the bile acid, ursodeoxy-
cholic acid (UDCA), has been shown to improve biochemical
parameters, histology, and survival in PBC and is widely recom-
mended [11,12]. In contrast, there is no effective pharmacother-
apy for PSC, although there is growing interest in the use of
intermediate dose UDCA (or its analogs) and antibiotics, at least
in a subset of patients [13]. Although their epidemiology, natural
history, and associated diseases are distinct, both PBC and PSC
have in common the ultimate progression to cholestasis and
ﬁbrosis, suggesting commonality in pathways and cell types
involved in the initiation and progression of disease.Pathogenic framework
The dynamic biliary epithelium
The concept of a dynamic proliferative epithelium was originally
termed ‘‘ductular reaction’’ over 50 years ago [14]. With respect3 vol. 58 j 575–582
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to proliferative characteristics at the ductular level, a number of
morphologically distinct proliferative responses have been
described both in animal models as well as human disease. While
historically the classiﬁcation of and terminology surrounding
ductular reaction has been variable and inconsistent, four distinct
ductular reactions are currently recognized (reviewed in [15]),
and a clearer categorization of proliferating cholangiocytes has
emerged. In general, the ductular reaction encompasses the pro-
liferation or expansion of existing ducts, or an expanded popula-
tion of differentiating hepatic progenitor cells that reside at the
interface of terminal cholangioles (the ﬁnest branches of the bil-
iary tree) and Canals of Hering. These bipotential hepatic progen-
itor cells can differentiate towards hepatocytes or cholangiocytes
[25].
Our current understanding of the histological characteristics
of the ductular reaction [16–18], molecular mechanism regulat-
ing this process [19,20], and the pathophysiological conse-
quences of cholangiocyte proliferation [21–23] have grown
greatly over the last years. This expansion of knowledge is due
primarily to advances in the development of both in vivo and
in vitro experimental models, the recognition of the heterogene-
ity of this diverse population of cells, and the recognition of a
hepatic progenitor cell population that can recapitulate embryo-
genesis of the biliary tree. Indeed, the ductular reaction involving
hepatic progenitor cells shares a number of morphological and
molecular properties (i.e., expression of morphogens, growth fac-
tors, and transcription factors) with ductal plate cells during
embryonic development of bile ducts (reviewed in [4]). Similar
to their role in embryogenesis, these morphogens contribute to
cellular crosstalk in the mature liver and regulate progenitor cell
fate, and, importantly, contribute to biliary repair processes
(reviewed in [4,26]).
Cholangiocytes respond to insult or injury through the expres-
sion of a repertoire of proinﬂammatory cytokines/chemokines
(e.g., tumor necrosis factor alpha (TNF-a), interleukin-6 (IL6),
and interleukin-8 (IL8)) [14–17], growth factors (e.g., platelet-
derived growth factor (PDGF), vascular endothelial growth factor
(VEGF), and transforming growth factor-beta (TGFb) [18–20]),
and morphogens (Hedgehog and Notch [24,25]). These molecules
function in an autocrine and/or paracrine manner to mediate cel-
lular events, including proliferation, apoptosis, vasculogenesis,
and ﬁbrosis, associated with the biliary repair response. Further-
more, secretion of these factors modiﬁes the periductular micro-
environment and mediates the recruitment of innate and
adaptive immune cells to protect against biliary insult or infec-
tion, and resident and recruited mesenchymal and endothelial
cells to repair and remodel the biliary tree. With respect to the
ductular reaction, a clearer picture is emerging of the molecular
events required for repair and remodeling. It is now recognized
that in an inﬂammatory environment, optimal viability and
growth of epithelial progenitors require hedgehog signaling
[24,26,27], while Notch signaling is necessary for speciﬁcation
of cholangiocyte fate [28] in a process mediated by marco-
phage-derived Wnt signaling [19]. It is likely that these proper-
ties of the reactive cholangiocyte, while necessary for repair
and remodeling, contribute to the pathogenesis of cholangiopa-
thies. Of further interest, recent data support the existence of
stem/progenitor cells residing in peribiliary glands [29]. This
repository of multipotent stem cells show phenotypic character-
istics of the hepatic progenitors found in the Canals of Hering.
Interestingly, the peribiliary glands are ﬁrst found at the levelJournal of Hepatology 201of the septal ducts and continue to the extrahepatic ducts [29],
suggesting that, in addition to providing a source of multipotent
cells for extrahepatic bile ducts, they are likely sources of biliary
epithelial cells involved in intrahepatic biliary remodeling pro-
cesses. Whether these cells are activated and follow a differenti-
ation pattern similar to the progenitor cells at the terminal
branches of the biliary tree remains to be determined.
An area that has also received considerable attention is the
neuroendocrine transdifferentiation of cholangiocytes in
response to cholestasis or injury. Indeed, several manuscripts
have characterized a cholangiocyte neuroendocrine phenotype,
that is, a compartment of ductal cells that secrete and respond
to a number of hormones, neuropeptides, and neurotransmitters
(reviewed in [30]). This property of reactive cholangiocytes con-
tributes to their increased proliferative capacity, and is likely
involved in the pathogenesis of cholangiopathies. Hence, the ini-
tiation of cholangiocyte reactivity, the induction of progenitor
cells and the resultant increase in intercellular communication
drive hepatobiliary repair mechanisms and, when dysregulated,
likely lie at the center of the pathogenic pathways of at least
some of the cholangiopathies. Ongoing investigations analyzing
the molecular mechanisms by which cytokines/chemokines,
growth factors, hormones, and morphogens function collectively
to initiate and perpetuate biliary repair and remodeling under
normal and pathological conditions are essential to understand
the etiology and pathogenesis of several cholangiopathies.
The gut-liver axis
Bile is a source of potential mediators of inﬂammation. Hepatic
bile is directly emptied into the duodenum and the bile compo-
nents are modiﬁed by the resident intestinal microﬂora. Selective
intestinal uptake of primary and bacterially modiﬁed bile acids
(secondary bile acids) results in their recycling back to the liver
through the portal circulation in a process known as enterohepat-
ic circulation. Moreover, a healthy intestine prevents the translo-
cation of large amounts of microbes and microbially derived
products. However, disruption of the intestinal barrier function
results in the translocation of large amounts of microbes and
microbially derived products. Through this route, the liver is
exposed to bacterially-derived products and xenobiotics, includ-
ing products that can induce inﬂammatory responses in multiple
hepatic cell types and contribute to chronic liver disease [31].
Therefore, bile composition is modiﬁed not only by canalicular
secretion from hepatocytes and cholehepatic shunting of bile
acids, but by the enterohepatic circulation of microbially-derived
products, modiﬁed endogenous molecules (e.g., secondary bile
acids) and xenobiotics. The potential exists, therefore, for the
composition of bile, including the presence of exogenous and
endogenous mediators of inﬂammation, to reﬂect, at least in part,
the diversity of resident enteric microbes, or the enteric microb-
iome. Conversely, the composition of bile may directly inﬂuence
the diversity of the gut microbiota. Indeed, it was recently dem-
onstrated that an increase in the bile acid, taurocholic acid,
induced by a high milk-derived-fat diet, promoted the growth
of the sulphite-reducing pathobiont, Bilophila wadsworthia. More-
over, this expansion was associated with the increased incidence
of colitis in IL10-deﬁcient mice [32]. Hence, metagenomics, or the
study of genetic material extracted from environmental samples,
coupled with advances in high-throughput DNA sequencing and
bioinformatics tools, has allowed the sequencing of microbial3 vol. 58 j 575–582 577
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communities, including those that reside on or in humans. Using
these techniques, it is now recognized that bacterial dysbiosis, or
a change in the normal bacterial composition, is found in the gut
of patients with cirrhosis [33] and inﬂammatory bowel disease
(reviewed in [34]). It seems likely, given the intimate anatomic
and physiologic relation between the gut and the liver, that the
composition and potential dysbiosis of the microbiome inﬂuence
hepatobiliary physiology, and likely contribute to the etiopatho-
genesis of cholangiopathies; yet deﬁnitive cause-effect relation-
ships in humans are lacking.
Cholangiocyte response to endogenous and exogenous insults
Several families of proteins are involved in recognition of poten-
tially injurious microbial components and products released from
injured or dying cells. The best characterized of these pathogen
recognition receptors (PRRs) are Toll-like receptors (TLRs) and
nucleotide-binding oligomerization domain proteins (NODs)
[28–30]. PAMPs, the microbial molecular signatures that activate
PRRs (e.g., Gram-negative bacterially-derived lipopolysaccharide,
LPS) induce TLR oligomerization and conformational changes in
the cytoplasmic portion of these receptors, the so-called Toll/IL-
1 receptor (TIR) domain. The TIR domains recruit signaling adap-
tor proteins (i.e., myeloid differentiation protein 88 [MyD88],
interleukin 1 receptor-associated kinases (IRAKs), and TIR
domain-containing adapter-inducing interferon-b (TRIF)). Signal
cascades are transduced via either MyD88 dependent or indepen-
dent (TRIF) pathways, culminating in the activation of transcrip-
tion factors, including MyD88 dependent nuclear factor kappa-B
(NF-jB) or TRIF dependent interferon regulatory transcription
factor 3 (IRF3). Enterohepatic circulation brings potential media-
tors of inﬂammation from the gut to the hepatic sinusoids. A vari-
ety of hepatic cell types, including the sinusoidal endothelial
cells, Kupffer cells, hepatocytes, hepatic stellate cells, dendritic
cells, and recruited bone marrow derived monocytes express
TLRs and, hence, recognize and respond to PAMPS through TLR
dependent upregulation of proinﬂammatory mediators and con-
tribute to repair processes [31]. Moreover, as others and we have
previously shown, cholangiocytes express multiple TLRs (and
associated molecular machinery) that upon pathogen recogni-
tion, initiate signaling cascades altering cholangiocyte physiology
and the extracellular milieu [15,31,32]. Hence, cholangiocytes are
capable of initiating or perpetuating an innate immune response
against potentially pathogenic insults (for a recent review see
[35]). Indeed, cholangiocyte TLR and subsequent NF-jB activa-
tion have been demonstrated in a variety of cell culture and ani-
mal models of cholangiocyte responses to pathogens [36–43]. We
have also recently demonstrated that stimulation of cultured
cholangiocytes with PAMPs induce the activation of not only
NF-jB, but also the rapid activation of the Ras/MAPK pathway,
both contributing to the expression of proinﬂammatory media-
tors and cholangiocyte proliferation [43].
In response to pathogen recognition, cholangiocytes produce
and secrete a number of pro-inﬂammatory cytokines/chemokines
(e.g., TNF-a, interleukin-6, interleukin-8) [40,41]. Human cholan-
giocyte expression of these proinﬂammatory mediators functions
as part of the biliary innate immune and repair responses and
alters the periductal cytokine networks mediating recruitment
and activation of T cells, macrophages, neutrophils, NK cells
and resident and recruited mesenchymal cells. Hence, the cholan-
giocyte proinﬂammatory signaling cascade, in response to lume-578 Journal of Hepatology 201nal insults, is likely an essential event initiating biliary repair
responses. Importantly, to avoid excessive innate immune
responses, many innate immune and epithelial cells initiate a
protective process of endotoxin tolerance. Endotoxin tolerance
is a phenomenon in which, following a robust initial response
to endotoxin insult (e.g., LPS) cells enter a transient state where
they exhibit reduced responsiveness to subsequent endotoxin
insult. Cholangiocytes exhibit endotoxin tolerance in culture
[38]. It was recently determined that following an initial endo-
toxin insult, using either the TLR4 ligand LPS, or the TLR1/2 ligand
PAM3CSK9, cultured cholangiocytes were less responsive to a
secondary treatment with LPS, as demonstrated by NFkB activa-
tion [38]. In this instance, endotoxin tolerance was regulated
through IRAK-M, a member of the interleukin-1 receptor-associ-
ated kinase family that functions as a negative regulator of TLR
signaling. The hypothesis that impaired endotoxin tolerance
may be a contributing factor in chronic inﬂammatory cholangiop-
athies (i.e., PSC) was also investigated [44]. Freshly isolated pri-
mary cholangiocytes, isolated from the PSC liver, exhibited
increased TLR expression compared to cholangiocytes isolated
from the non-diseased control liver, and did not develop endo-
toxin tolerance after repeated endotoxin exposure. Further evi-
dence supported that this lack of endotoxin tolerance in
isolated cholangiocytes was secondary to excessive pro-inﬂam-
matory mediators (i.e., IFNa and TNFb) present in the diseased
livers, which was maintained in short-term culture. Importantly,
cholangiocytes isolated from PSC livers, when maintained in pro-
longed culture in the absence of inﬂammatory mediators,
reverted to a phenotype capable of initiating endotoxin tolerance.
These results are consistent with the hypothesis that the inﬂam-
matory milieu of the diseased liver (i.e., cellular crosstalk in an
inﬂammatory microenvironment), coupled with persistent expo-
sure and response to PAMPs, promotes a persistent inﬂammatory
phenotype of cholangiocytes.
The potential role of enteric microbes, cholangiocyte TLRs and
associated endotoxin tolerance, in the background of genetic sus-
ceptibility in hepatobiliary pathophysiology, was recently exem-
pliﬁed in a model of sclerosing cholangits using cystic ﬁbrosis
transductance regulator (CFTR) deﬁcient mice [45]. In the liver,
CFTR is expressed exclusively by cholangiocytes and is essential
for alkalinization of bile and choleresis. In humans, the disease
cystic ﬁbrosis (CF) involves many organs, including the liver,
where a subset of patients develops hepatobiliary complications
including sclerosing cholangitis-like architecture. In the CFTR
deﬁcient animal, a ‘‘leaky gut’’, induced by dextran sodium sul-
fate treatment, and hence exposure of the liver and biliary tree
to enteric microbial products, contributed to hepatobiliary
pathology via exaggerated TLR4 signaling and reduced endotoxin
tolerance. Hence, using this model, Fiorotto et al. demonstrated
support for a ‘‘two-hit’’ hypothesis of exogenous insults (microbi-
ally derived) inducing hepatobiliary disease (sclerosing cholangi-
tis) in genetically susceptible (CFTR deﬁcient) animals. It seems
likely, therefore, that PRRs initiate an activation cascade that if
exaggerated, altered, or chronic, could contribute to disease initi-
ation or progression. For example, in extreme cases (e.g., second-
ary sclerosing cholangitis induced by Cryptosporidium parvum),
cholangiocyte response to microbial insult results in cholestasis
and periductal ﬁbrosis [46].
In addition to microorganisms or microbially derived mole-
cules, several endogenous molecules, including several present
in bile, have been reported to activate TLRs [28]. Indeed, products3 vol. 58 j 575–582
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released from injured or dying cells (damage-associated molecu-
lar patterns, DAMPs), including HMGB1, S100A8/S100A9, and
heat shock proteins, activate a variety of TLRs and/or DAMP
receptors [47]. To date, the levels of DAMPs in human bile under
normal and pathophysiological conditions, as well as the cellular
expression of DAMP receptors in the liver, the signaling cascades
initiated by these receptors, and the physiological consequences
of DAMPs on hepatic function have not been fully investigated.
Furthermore, other components of bile have been demonstrated
to mediate inﬂammatory processes including oxysterols, oxygen-
ated derivatives of cholesterol. These molecules can be non-enzy-
matically produced in inﬂammatory environments and have been
identiﬁed in bile obtained from patients with inﬂammatory bili-
ary disorders [47]. One of these oxysterols, 22(R)-hydroxycholes-
terol, was demonstrated to increase the levels of cyclooxygenase-
2 in cholangiocarcinoma cells via a p38 MAPK dependent mech-
anism of mRNA stabilization [48]. Furthermore, treatment of cul-
tured cholangiocytes with selected oxysterols rapidly activates
both cholangiocyte NF-jB and MAPK pathways and induces cho-
langiocyte expression of interleukin-6 and interleukin-8 (O’Hara
and LaRusso, unpublished observations). Thus, the role of DAMPS,
endogenous components of bile such as bile acids, nucleotides
and oxysterols in mediating signaling cascades in cholangiocytes,
while a promising area of investigation, remains ill-deﬁned, as
does the role of these endogenous mediators of inﬂammation in
hepatobiliary pathophysiology in general and cholangiopathies
in particular (Fig. 2).
Hence, cholangiocytes exist in an environment rich in poten-
tial mediators of inﬂammation and are in constant communica-
tion with resident and recruited cells as well as the intestinal
tract. How cholangiocytes, throughout the biliary tree, respond
to exogenous and endogenous insults, including the precise sig-
naling cascades initiated by these insults, is an active area of
research that continues to provide insight into the innate
immune/proinﬂammatory function of this epithelium. A more
comprehensive understanding of (i) how the gut inﬂuences hepa-
tic function or dysfunction and the molecular mechanisms by
which putative injurious molecules stimulate cholangiocyte reac-
tivity; (ii) how the induction of cholangiocyte reactivity inﬂu-
ences the epithelia, resident and recruited mesenchymal and
immune cells, and (iii) the molecular mechanisms and genetic
variation that contribute to pathogenic perpetuation of cholan-
giocyte reactivity and the ductular reaction, will undoubtedly
improve our management of many cholangiopathies and open
avenues for potential therapeutics. This in turn will contribute
to our understanding of how cholangiocytes (and bile) function
as central players in enterohepatic physiology, yet may become
targets for disease and destruction.
Regulatory mechanisms involved in cholangiocyte activation
Protein coding genes perform the essential physiological func-
tions of the cell; however, only 2% of the human genome encodes
proteins, while the vast majority is transcribed largely as long
and short non-coding RNAs (ncRNAs) [48,49]. It has become
increasingly clear that one class of these ncRNAs, miRNAs, play
an essential role in cholangiocyte function. Indeed, recent studies
indicate that miRNA-mediated post-transcriptional pathways are
critical to host cell regulatory responses in a variety of cholangio-
cyte processes including proliferation [50], apoptosis [51,52],
and, particularly germane to this review, response to microbialJournal of Hepatology 201insult [53,54]. For instance, cultured human cholangiocytes
express let-7 miRNA family members, which under normal phys-
iological conditions, post-transcriptionally downregulate TLR4
expression. Following exposure of cultured human cholangiocyte
to microbes (i.e., C. parvum) or microbial products (i.e., LPS), the
expression of let-7 decreased resulting in the increased expres-
sion of TLR4 in an NF-kB-dependent manner [53,54]. Hence,
expression of cholangiocyte innate immune-associated genes is
a highly regulated process, occurring through both transcrip-
tional and post-transcriptional mechanisms, involving miRNAs,
that assures that the epithelium recognizes and responds to
insults, but does not induce injury through an inappropriate
and/or hyper-reactive response.
In addition to transcriptional and post-transcriptional events
that regulate the cholangiocyte response to insult and repair pro-
cesses, the genetic background of the individual (as well as epige-
netic modiﬁcations to cholangiocyte chromatin) is essential for
biliary homeostasis. Genome wide association studies (GWAS)
have identiﬁed allelic variants associated with both PBC and
PSC including both human leukocyte antigen (HLA) and non-
HLA associations [55,56]. For example, GWAS analysis of Cana-
dian and U.S. subjects revealed strong association between PBC
and multiple loci across the HLA class II region, with the strongest
association at the HLA-DQB1 loci. Furthermore, strong associa-
tions were observed at non-HLA loci including IL12A and IL12RB2
(encoding the cytokine interleukin-12A and the interleukin-12
receptor b2 loci, respectively) [55]. GWAS analysis of PSC has
reproducibly identiﬁed association at the HLA-B loci [58,59], as
well as non-HLA associations at the MST1 loci (encoding macro-
phage stimulating-1) [58,59]. While this approach has identiﬁed
several disease associated loci, these variants account for only a
portion of the heritable disease risk. While the genetic basis of
the host certainly plays a principle role in disease initiation and
progression, we are just now beginning to understand the com-
plex molecular regulatory networks involved in carrying out
the genetic program and epigenetic modiﬁcations of DNA that
heritably alter cellular phenotype through meiotic and mitotic
events. Among the relatively unexplored regulatory mechanisms
that function in the cholangiocyte, and may be involved in cho-
langiocyte activation, are these epigenetic phenomena. Besides
gene regulatory proteins (transcription factors), epigenetic mech-
anisms play an essential role in the transcriptional control of
gene expression. These epigenetic mechanisms change the acces-
sibility of chromatin through DNA methylation and histone mod-
iﬁcations, and epigenetic modulators are likely critically involved
in the regulation of inﬂammatory processes associated with chol-
angiopathies [57]. Epigenetic modiﬁcations in the heritability of
these idiopathic diseases (i.e., parent-of-origin effects) should
be considered; however, epigenetic modiﬁcations can result in
altered chromatin accessibility transmitted through mitosis,
and hence cell progeny. These modiﬁcations may be involved in
the persistence of a proinﬂammatory phenotype, and perhaps
contribute to the etiopathogenesis of both PSC and PBC. Genetic
predispositions, as well as epigenetic, transcriptional, and post-
transcriptional regulation of gene expression all contribute to cel-
lular phenotype and each works as a component of the gene
expression circuitry and hence must be considered when
attempting to understand cellular function and dysfunction.
While the dynamic nature of the biliary epithelia has received
considerable attention over the last two decades, a direct causal
link between these processes and the etiopathogenesis of3 vol. 58 j 575–582 579
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Fig. 2. Cholangiocytes exist in an environment rich of potential mediators of cellular injury. Through enterohepatic circulation: (1) the liver is exposed to bacterially
derived products (PAMPs), xenobiotics and endogenous mediators of inﬂammation (DAMPs). Portal blood ﬂows into hepatic sinusoids, where a variety of resident and
recruited cells can recognize and respond to these potential insults. Ultimately, hepatocytes take up, modify, and excrete these molecules into the canaliculus. Canalicular
bile percolates through the biliary tree where cholangiocytes recognize and react to these potential insults through the increased release and response to repair associated
chemokines/cytokines, growth factors, and morphogens, initiating both autocrine and paracrine signaling cascades (2). A more comprehensive understanding of the role of
the gut in hepatic function and the molecular networks mediating injury induced growth and repair, as well as the cholangiocyte epigenetic phenomena, and the genetic
variation (3) that contribute to the perpetuation of this phenotype and sequelae, including ﬁbrogenesis and carcinogenesis, will undoubtedly open avenues for potential
therapeutic approaches.
Reviewcholangiopathies has yet to been established. In addition to pro-
liferation and repair, damaged cholangiocytes initiate processes
resulting in their removal. One of these processes, apoptosis
(i.e., programmed cell death), has been described as a potential
contributing factor in the pathogenesis of cholangiopathies
(reviewed in [5]). Similar to apoptosis and in many instances a
precursor to the extrinsic apoptotic pathway (i.e., targeted
destruction by lymphocytes), permanent withdrawal from the580 Journal of Hepatology 201cell cycle (i.e., senescence) functions as a protective mechanism
to remove damaged cells from the population. The accumulation
of senescent cholangiocytes has been identiﬁed in both PBC and
PSC [58–62]. We have recently conﬁrmed the existence of senes-
cent cholangiocytes in PSC tissue (unpublished data). The induc-
tion of senescence holds promise as a potential link between
persistent inﬂammation, cholangiocyte proliferation, and the
etiopathogenesis of select cholangiopathies. Most cells, in both3 vol. 58 j 575–582
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culture and in vivo, have a ﬁnite capacity to proliferate, a process
intimately associated with telomere shortening, and linked to the
morbidities associated with aging (reviewed in [63,64]). Cholan-
giocytes from normal livers maintain telomere length with
increased age, likely reﬂecting an increased capacity of prolifera-
tion and a resistance to age-associated senescence [65]. However,
upon recognition of persistent and/or aberrant proliferative sig-
nals (i.e., oncogene-induced) and/or recognition of the accumula-
tion of persistent DNA damage (i.e., DNA strand breaks), cells can
initiate the senescence program through the activation of one or
both of the strong tumor suppressor pathways (p16INK4A/Reti-
noblastoma or p53/p21WAF) (reviewed in [66]) and permanent
silencing of cell cycle progression-related genes (i.e., epigenetic
silencing of E2F-responsive genes), that likely involves microR-
NAs [67]. Intriguingly, senescent cells frequently transition to a
senescence-associated secretory phenotype (SASP), characterized
by the robust secretion of chemokines, cytokines, growth factors,
and matrix metalloproteases (MMPs) that function in repair/
remodeling and recruiting of immune cells (reviewed in
[64,68]). It seems likely that prolonged proliferative signals, cou-
pled with the potential accumulation of DNA damage induced
from the inﬂammatory milieu, promote the induction of a mech-
anism to remove the damaged cells from the population. The
potential roles of senescent cholangiocytes in repair/remodeling
and inﬂammation, remain to be explored in detail, particularly
as a potential contributing factor in the pathogenesis of
cholangiopathies.Conclusions and perspectives
Over the past three decades, our appreciation of cholangiocytes
as a heterogenous, highly dynamic population of cells, has con-
tributed to the tremendous growth in our knowledge of cholan-
giocyte function and dysfunction. Most of these advances have
required the development and implementation of novel and
innovative experimental models, and the evolution of concepts
that allow the generation of hypotheses leading to relevant ques-
tions. It is now generally accepted that the cholangiocyte is an
active and important participant in normal liver function and,
rather than being only a target cell of cholangiopathies, actively
contributes to the pathogenesis of disease. Although the mecha-
nisms underlying the development of acquired cholangiopathies
are still emerging, common pathogenic pathways, genetic sus-
ceptibilities, and epigenetic phenomena continue to emerge.
Future research to understand the interaction of environmental
elements, including the direct communication between gut
microbes and hepatic physiology, with the genetically and
epigenetically regulated host responses of cholangiocytes, will
almost certainly shed light on the pathogenesis of cholangiopa-
thies. Such knowledge will provide the framework within
which to develop preventive and therapeutic strategies for
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